Smith S F
Department of Medicine, Charing Cross and Westminster Medical School, London, UK.
Thorax. 1996 Oct;51(10):1057-9. doi: 10.1136/thx.51.10.1057.
Glucocorticoids (glucocorticosteroids, corticosteroids) have an important place in the treatment of many inflammatory conditions including those of the respiratory tract. Their mechanisms of action include both the suppression of proinflammatory mediators and the upregulation of at least one anti-inflammatory protein, lipocortin 1 (also known as annexin 1). Lipocortin 1 has been convincingly demonstrated to mediate the anti-inflammatory effects of glucocorticoids in a variety of in vivo and in vitro models of inflammation. The actions of lipocortin 1 in the lung have not been fully elucidated. If, as initial studies suggest, its effects in the respiratory tract are shown to be anti-inflammatory, it is possible that administration of lipocortin 1 peptides, or other drugs based on the active site of lipocortin 1, might prove to be useful agents for the control of respiratory tract inflammation.
糖皮质激素（糖皮质类固醇、皮质类固醇）在包括呼吸道疾病在内的多种炎症性疾病的治疗中占有重要地位。它们的作用机制包括抑制促炎介质以及上调至少一种抗炎蛋白——脂皮质蛋白1（也称为膜联蛋白1）。在多种体内和体外炎症模型中，脂皮质蛋白1已被确凿证明可介导糖皮质激素的抗炎作用。脂皮质蛋白1在肺部的作用尚未完全阐明。如果如初步研究所表明的那样，其在呼吸道中的作用被证明具有抗炎性，那么给予脂皮质蛋白1肽或基于脂皮质蛋白1活性位点的其他药物可能会被证明是控制呼吸道炎症的有效药物。
